Emodin in Skeletal Muscle Ischemia-Reperfusion: Model Validity and Analytical Concerns [Letter]

Dear editor

We read with interest the study by Yigit et al1 on the antioxidant effects of emodin in a rat model of skeletal muscle ischemia-reperfusion (I/R) injury. While the investigation addresses a clinically relevant question, several methodological issues warrant careful consideration.

First, the validity of the infrarenal aortic clamping model is questionable given the substantial collateral circulation of the rat hindlimb. Rosero et al demonstrated that infrarenal aortic occlusion produces significantly milder ischemic injury than tourniquet application, because the rat lower limb possesses a well-developed collateral network that partially sustains perfusion during clamping.2 This collateral circulation likely explains why the ischemia duration of 45 minutes in the present study produced only moderate histopathological damage. More critically, if collateral flow varies substantially between individual animals, the actual ischemic burden delivered to the gastrocnemius muscle may differ considerably across subjects, introducing uncontrolled heterogeneity into the dose–response relationship between emodin and tissue protection. The authors did not verify the adequacy of ischemia (eg, via laser Doppler perfusion imaging or measurement of tissue metabolites) in any animal, leaving the actual ischemic insult unquantified.

Second, the MDA measurement via TBARS is methodologically problematic. The TBARS assay lacks specificity for MDA, as numerous MDA-unrelated species—including bile pigments, amino acids, and carbohydrates—react with thiobarbituric acid.3 Furthermore, the assay generates artifactual MDA during the heating step, with TBA-based methods yielding two- to six-fold higher values than GC-MS measurements in biological samples.3 Given that MDA was the principal biochemical endpoint supporting the study’s conclusion that emodin “inhibits lipid peroxidation”, the reliance on an assay with such limited specificity and known overestimation substantially weakens the central claim.

Third, the semiquantitative histopathological scoring lacks essential validation. The authors scored four parameters on a 0–3 scale but did not report inter-observer or intra-observer reliability. Semiquantitative scoring systems for skeletal muscle ischemia require rigorous validation; Sanz-Nogués et al developed a multiparametric scoring tool with Kendall’s W of 0.77–0.94, demonstrating that such reproducibility is achievable and necessary.4 Without reliability data, the observed treatment effects on histopathological injury cannot be distinguished from observer-dependent scoring variability.

In summary, the unverified ischemic model, the nonspecific MDA assay, and the unvalidated histopathological scoring collectively limit the strength of the conclusions.

Funding Statement

There is no funding to report.

Disclosure

None of the authors have any conflicts of interest in this communication.